Prevention and treatment of acute GvHD

Bone Marrow Transplantation

Volumn 41, Issue SUPPL. 2, 2008, Pages

  Messina, C ^a   Faraci, M ^b   de Fazio, V ^b   Dini, G ^b   Calo M P ^a   Calore, E ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; DENILEUKIN DIFTITOX; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; METHOXSALEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VISILIZUMAB;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TOXICITY; CHOLESTASIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DONOR LYMPHOCYTE INFUSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GRAFT RECIPIENT; GROWTH DISORDER; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOMAGNESEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; INFECTION; LOW DRUG DOSE; LYMPHOCYTOPENIA; LYMPHOPROLIFERATIVE DISEASE; MESENCHYMAL STEM CELL TRANSPLANTATION; MONOTHERAPY; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PUVA; QUALITY OF LIFE; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SEIZURE; STOMACH ULCER; SUICIDE GENE THERAPY; T CELL DEPLETION; THERAPY RESISTANCE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; WHOLE BODY RADIATION;

CHILD; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; STEROIDS; T-LYMPHOCYTES, REGULATORY; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45749117691     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.57     Document Type: Article

References (59)

1. Bacigalupo A. Management of acute graft-versus-host-disease. Br J Haematol 2007; 137: 87-98.
2. Blaise D, Kuentz M, Container C. Randomized trail of bone marrow versus lenograstim primed blood cell allogeneic transplantation. J Clin Oncol 2000; 18: 537-546.
3. Couban S, Simpson R, Barnett MJ, Bredeson C. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 104: 649-654.
4. Schmitz N, Beksac M, Hasenclever D, Bacigalupo A. Ruutu T, Nagler A et al. Transplantation of mobilized peripheral blood cells to HLA identical siblings with standard risk leukaemia. Blood 2002; 100: 761-767.
5. Rocha V, Wagner JE, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. N Eng J Med 2000; 342: 1846-1854.
6. Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962-2971.
7. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE et al. Haematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Eng J Med 2001; 334: 1860-1861.
8. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW et al. T-cell depletion of HLA-identical transplants in leukaemia. Blood 1991; 78: 2120-2130.
9. Aversa F, Tabilio A. Velardi A. Cunningham I. Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Eng J Med 1998; 339: 1186-1193.
10. Hows J, Bradley BA, Gore S, Downie T, Howard M, Gluckman E. Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplant 1993; 12: 371-380.
11. Finke J, Bertz H, Schmoor C, Veelken H, Behringer D, Wäsch R et al Allogeneic bone marrow transplantation from nrelated donors using in vivo anti-T-cell globulin. Br J Haematol 2000; 111: 303-313.
12. Byrne JL, Stainer C, Cull G, Haynes AP, Bessell EM, Hale G et al. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplant 2000; 25: 411-417.
13. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: Efficacy and side effects. Bone Marrow Transplant 2005; 35: 225-231.
14. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host-disease, chronic lung dysfunction, and late transplant-related mortality: Long term follow up of a randomised trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560-565.
15. Trenado A, Sudres M, Tang Q, Maury S, Charlotte F. Grégoire S et al. Ex vivo-expanded CD4 CD25 immuno-regulatory T cells prevent graft-versus-host-disease by inhibiting activation differentiation of pathogenic T cells. J Immunol 2006; 176: 1266-1273.
16. Storb R, Leisenring W, Anasetti C, Appelbaum FR, Buckner CD, Bensinger WI et al. Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate, cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. Blood 1994: 83: 2749-2750.
17. Storb R, Pepe M, Deeg HJ, Anasetti C, Appelbaum FR, Bensinger W et al Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Blood 1992; 80: 560-561.
18. Storb R, Pepe M, Anasetti C, Appelbaum FR, Beatty P, Doney K et al What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76: 1037-1045.
19. Bacigalupo A, van Lint MT, Occhini D, Gualandi F, Lamparelli T, Sogno G et al. Increased risk of leukaemia with high dose cyclosporine A after allogeneic marrow transplantation. Blood 1991; 77: 1423-1428.
20. Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al Graft versus host disease prophylaxis with low dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA identical sibling bone marrow transplantation: Results of a randomized trial. Blood 2000; 95: 1572-1579.
21. Lanino E, on behalf of the AIEOP-BMT Group Pretransplant CYA. Preliminary results of a randomized study in pediatric recipients of unrelated-donor BMT. Blood 1999; 94 (Suppl 1): 392.
22. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068.
23. Yanik G, Levine JE, Ratanatharathorn V, Dunn R, Ferrara J, Hutchinson RJ. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 26: 161-167.
24. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004: 34: 621-625.
25. Klyshnenkova EN, Mosca J, McIntosh KR. Human mesenchymal stem cells suppress allogeneic T cell responses in vitro: Implications for allogeneic transplantation. Blood 1998; 92: 642a.
26. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in viro. Exp Hematol 2002; 30: 42-48.
27. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK et al Co-transplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389-398.
28. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE et al. Donor-derived mesenchymal stem cells are immunogeneic in an allogeneic host and stimulate donor graft rejection in a non-myeloablative setting. Blood 2006; 15: 108 2114-2120.
29. Alcindor T, Gorgun G, Miller KB, Roberts TF, Sprague K, Schenkein DP et al. Immunologic mechanism of extracorporeal photochemotherapy (ECP) in chronic GVHD. Blood 2001; 98: 650a (abstract 2729).
30. Peritt D. Potential mechanism of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 7-12.
31. Chan G, Foss FM, Roberts T, Sprague K, Schenkein D, Miller KB. Decreased acute and chronic graft versus host disease with early full donor engraftment following a pentostatin-based preparative regimen for allogeneic bone marrow transplant in high-risk patients. Blood 2001; 98: 383a (abstract 1612).
32. Ruggeri L, Shlomchik WD. Donor-vs-recipient alloreactive NK cells prevent GVHD by killing host APC in MHC disparate hematopoietic transplants. Blood 2001; 98: 813a (abstract 3378).
33. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukaemia with T-cell-depleted stem cell from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
34. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Non-myeloablative stem cell transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
35. Kottardis PD, Chakraverty, Milligan DW, Chakrabarti S, Robinson S, Chopra R et al. A non-myeloablative regimen for allogeneic stem cell transplantation with a low incidence of GVHD. Bone Marrow Transplant 2000; 25: S26.
36. Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005; 353: 1321-1331.
37. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995; 345: 1144-1146.
38. Anasetti C, Lin A, Nademanee A, Gluckman E, Messner H, Beatty P et al A phase II,III randomized double blind, placebo-controlled multicentre trial of humanised anti-Tac for prevention of acute graft-versus-host disease in recipients of marrow transplant from unrelated donors. Blood 1995; 86 (Suppl 1): 621a.
39. Holler E, Kolb HJ, Mittermüller J, Kaul M, Ledderose G, Duell T et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNF α) release in the course of pretransplant conditioning: Role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF α (MAK 195F). Blood 1995; 86: 890-899.
40. Blazar BR. Response of 443 patients to steroids as primary therapy for acute GvHD: Comparison of grading system. Biol Blood Marrow Transplant 2002; 47: 387-394.
41. Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scimé R, Locatelli F et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6 methylprednisolone: A multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92: 2288-2293.
42. Cragg L, Blazar BR, Defor T, Kolatker N, Miller W, Kersey J et al. A randomized trial comparing prednisone with antithymocyte globulin/ prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6 441-447.
43. Van Lint MT, Milone G, Leotta S, Uderzo C, Scimè R, Dallorso S. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006; 107: 4177-4181.
44. Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D. Novel approaches to the therapy of steroid resistant acute graft versus host disease. Biol Blood Marrow Transplant 2004; 10: 655-668.
45. Antin JH. Approaches to graft-vs-host disease. Paediatr Transplant 2005; 9: 71-75.
46. Furlong T, Storb R, Anasetti C, Appelbaum FR, Deeg HJ, Doney K et al Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplant 2000; 26: 985-991.
47. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83-89.
48. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors on non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients. A cohort study. Blood 2003; 102: 2768-2776.
49. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C et al Tumor necrosis factor alpha blockade for the treatment of acute GVHD. Blood 2004; 104: 649-654.
50. Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J et al. Treatment of steroid-refractory acute graft-verus-host-disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 2001; 98: 2052-2058.
51. Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gopley T et al A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 2002; 99: 2712-2719.
52. Jacobsohn DA, Vogelsang GB. Novel pharmacotherapeutic approaches to prevention and treatment of GvHD. Drugs 2001; 62: 879-889.
53. Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72: 1924-1929.
54. Bolaños-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005; 20: 2661-2668.
55. Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390-1397.
56. Greinix HT, Knobler RM, Worel N, Schneider B, Schneeberger A, Hoecker P et al. Intensified extracorporeal photochemotherapy in severe acute graft-versus-host disease results in long-term improved survival. Haematologica 2006; 3: 555-580.
57. Greinix HT, Socié G, Bacigalupo A, Holler E, Edinger MG, Apperley JF et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant 2006; 38: 265-273.
58. Messina C, Locatelli F, Lanino E, Uderzo C, Zacchello G, Cesaro S et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 118-127.
59. Komanduri KV, Couriel D, Champlin RE. disease after allogeneic stem cell transplantation: Evolving concepts and novel therapies including photopheresis. Biol Blood Marrow Transplant 2006; 12: 1-6; review.